2025年商业健康保险对创新药械的总赔付金额约为147亿元

Core Insights - The meeting highlighted the rapid growth and diversification of commercial health insurance in China, driven by policy support and market demand, with an average annual compound growth rate exceeding 20% over the past decade [1][4] - The industry is expanding its coverage to include innovative treatments and technologies, with a projected total compensation amount for innovative drugs and devices reaching approximately 14.7 billion yuan by 2025, reflecting a compound annual growth rate of 70% [1][4] Group 1: Industry Development - The commercial health insurance sector has seen a significant increase in the number of products available, with over 11,000 medical insurance products currently on the market [1] - The industry has incorporated high-value treatments such as CAR-T therapy and proton therapy into its coverage, enhancing the service capabilities of health insurance [1][4] Group 2: Future Directions - The insurance industry is urged to align with national goals for health development, respond to market needs, and maintain the fundamental principles of commercial insurance while improving product offerings and service quality [2][4] - The China Insurance Industry Association is committed to strengthening industry self-discipline and enhancing collaboration with health, medical, and academic organizations to promote coordinated development and mutual benefits [2][5]